QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 nextcure-doses-first-us-patient-with-sim0505-in-global-phase-1-cancer-trial-targets-proof-of-concept-data-by-1h-2026

First U.S. patient dosed at a mid-tier dose level where multiple responses have been observedMulti-regional trial to accelerate...

 nextcure-q2-eps-1129-misses-039-estimate

NextCure (NASDAQ:NXTC) reported quarterly losses of $(11.29) per share which missed the analyst consensus estimate of $(0.39) b...

 us-stocks-likely-to-open-on-a-mixed-note-intel-philips-66-centene-charter-earnings-in-focus

U.S. stock futures swung between gains and losses on Friday after ending on a mixed note on Thursday. Futures were mixed.

 nextcure-stock-skyrockets-nearly-45-in-after-hours-trading-after-sharing-preclinical-data-for-brittle-bone-disease

NextCure Inc. (NASDAQ: NXTC) surged by 44.87% in after-hours trading on Thursday, following presentation of new preclinical da...

 nextcure-presented-new-preclinical-data-in-a-well-established-model-of-osteogenesis-imperfecta--demonstrating-that-treatment-with-nc605-achieved-improved-bone-microarchitecture-and-reduced-fracture-incidence-compared-to-anti-sclerostin-treatment

BELTSVILLE, Md., July 24, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company com...

 piper-sandler-maintains-overweight-on-nextcure-lowers-price-target-to-15

Piper Sandler analyst Edward Tenthoff maintains NextCure (NASDAQ:NXTC) with a Overweight and lowers the price target from $3...

 nextcure-enacts-1-for-12-reverse-stock-split-shares-begin-trading-today-on-adjusted-basis

On July 14, 2025, NextCure, Inc., a Delaware corporation (the "Company"), effected a one-for-twelve (1:12) reverse stoc...

 nextcure-and-ligachembio-announces-they-will-present-trial-in-progress-poster-for-lncb74-a-b7-h4-targeted-antibody-drug-conjugate-as-monotherapy-in-participants-with-advanced-solid-tumors-at-american-society-of-clinical-oncology-2025

LNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and...

 nextcure-q1-eps-039-beats-040-estimate

NextCure (NASDAQ:NXTC) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.40) by 2...

 hc-wainwright--co-reiterates-buy-on-nextcure-maintains-3-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates NextCure (NASDAQ:NXTC) with a Buy and maintains $3 price target.

 hc-wainwright--co-reiterates-buy-on-nextcure-lowers-price-target-to-3

HC Wainwright & Co. analyst Emily Bodnar reiterates NextCure (NASDAQ:NXTC) with a Buy and lowers the price target from $...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION